Neoadjuvant chemotherapy is cancer treatment given before surgery, with the primary goal of shrinking a tumor so it’s easier to remove. While most people think of chemotherapy as something that follows an operation, giving it beforehand can make surgery less extensive, preserve more healthy tissue, and in some cases make an otherwise inoperable tumor removable. Oncologists use neoadjuvant therapy for more than a dozen types of cancer, including breast, colon, lung, prostate, and rectal cancer.
Why Chemotherapy Before Surgery
The logic is straightforward: a smaller tumor is easier to operate on. But neoadjuvant chemotherapy does more than just shrink things down. It gives your oncologist real-time information about whether your cancer responds to a particular drug regimen. If the tumor shrinks significantly during treatment, that’s strong evidence the drugs are working. If it doesn’t respond, your team can pivot to a different approach before surgery rather than discovering months later that the drugs weren’t effective.
This “live test” of drug sensitivity has real predictive power. Studies of breast cancer patients show that those whose tumors visibly shrink after the first cycles of treatment almost always continue responding. Patients whose tumors grow during early treatment consistently continue to progress. That early signal helps oncologists make faster, better-informed decisions about the rest of your treatment plan.
What Pathologic Complete Response Means
The best-case outcome of neoadjuvant chemotherapy is something called a pathologic complete response, or pCR. This means that when the surgeon removes the tissue where the tumor was, a pathologist examines it under a microscope and finds no remaining invasive cancer cells. It doesn’t necessarily mean the cancer is cured, but it’s a powerful prognostic sign.
A large phase III trial published in the Annals of Oncology found that patients who achieved pCR had a 60% lower risk of disease recurrence or death compared to those with residual cancer. That benefit held across all molecular subtypes of breast cancer. pCR rates vary widely depending on cancer type and treatment regimen, ranging from about 12% with standard approaches to nearly 28% with more intensive protocols.
Cancers Where It’s Commonly Used
Breast cancer is probably the most well-known application. Neoadjuvant chemotherapy is standard for inflammatory breast cancer, certain HER2-positive cancers, and triple-negative breast cancer. One of its clearest benefits here is allowing breast-conserving surgery instead of mastectomy. In a clinical trial of triple-negative breast cancer patients, 68% of those who became eligible for breast conservation after neoadjuvant treatment were able to keep their breast, including 56% of women who were initially told they’d need a mastectomy but whose tumors shrank enough to change the surgical plan.
For non-small cell lung cancer that has spread to nearby lymph nodes, neoadjuvant chemotherapy (sometimes combined with radiation or immunotherapy) is a common first step before attempting surgical removal. In rectal cancer, the approach has evolved into what’s called total neoadjuvant therapy, where all chemotherapy and radiation are delivered before surgery rather than splitting treatment before and after.
Total Neoadjuvant Therapy in Rectal Cancer
This approach has shown particularly strong results. The RAPIDO trial found that giving all systemic treatment before surgery doubled the rate of pathologic complete response compared to the traditional sequence (28% versus 14%). Patients were also far more likely to actually finish their full chemotherapy course: 85% completed treatment in the total neoadjuvant group versus 66% in the standard group. That matters because many patients struggle to tolerate chemotherapy after major abdominal surgery, so moving it earlier means more people get the full benefit.
The PRODIGE-23 trial confirmed similar advantages, with disease-free survival of 76% in the total neoadjuvant group compared to 69% with standard treatment. Perhaps most notably, the OPRA trial showed that 58% of patients in one treatment sequence were able to avoid permanent surgery altogether through an organ-preservation strategy, keeping their rectum intact when imaging and examination showed no remaining disease.
How Long Treatment Typically Takes
The number of chemotherapy cycles before surgery depends on the cancer type and how well the tumor responds. Three to four cycles is the most common range. For ovarian cancer, a retrospective analysis from Memorial Sloan Kettering found no meaningful difference in outcomes between three and four cycles, but five or more cycles before surgery was associated with worse survival, even when surgeons achieved complete tumor removal. The takeaway: more isn’t necessarily better, and the goal is to get to surgery once the tumor has responded adequately.
Response is typically checked with imaging scans after two to three cycles. If the tumor is shrinking as expected, your team will schedule surgery. If not, they may switch to a different drug combination or reconsider the surgical plan. The interval between your last chemotherapy dose and the operation is usually a few weeks, enough time for your blood counts to recover and your body to handle the stress of surgery.
Side Effects and Surgical Risks
The side effects of the chemotherapy itself are the same whether it’s given before or after surgery: fatigue, nausea, hair loss, increased infection risk, and other effects that vary by drug regimen. The unique concern with neoadjuvant treatment is whether weakening the immune system and slowing cell division before an operation leads to more surgical complications, particularly wound healing problems and infections.
A meta-analysis of 14 studies covering over 3,400 breast cancer patients examined exactly this question. The surgical site infection rate was slightly higher in the neoadjuvant group (7.2% versus 4.9%), but the difference was not statistically significant. The researchers concluded that neoadjuvant chemotherapy does not meaningfully increase infection risk for patients undergoing breast reconstruction after their cancer surgery. While chemotherapy does slow cell division and can delay wound healing in theory, the clinical data suggests this doesn’t translate into a significant real-world problem for most patients.
How It Differs From Adjuvant Chemotherapy
Adjuvant chemotherapy is the more familiar version: treatment given after surgery to kill any microscopic cancer cells that might remain. Neoadjuvant chemotherapy uses the same drugs but flips the sequence. The key advantages of going first are tumor shrinkage (potentially enabling less radical surgery), the ability to observe whether the drugs actually work against your specific cancer, and in some cases higher completion rates since patients tolerate chemotherapy better before surgery than after.
The tradeoff is that surgery is delayed while you undergo treatment, which can feel psychologically difficult when you know a tumor is still inside your body. There’s also a small risk that the cancer could progress during treatment if the drugs turn out to be ineffective, though early imaging checks are designed to catch this. For most cancers where neoadjuvant therapy is recommended, the data shows equivalent or better long-term survival compared to the surgery-first approach, with the added benefit of less extensive operations and better information to guide the rest of treatment.